Raisecare Completes Over RMB 100 Million Series B Financing to Accelerate Advancements in Life Sciences and In Vitro Diagnostics

VCBeat has learned at the earliest opportunity,Recently, Qingdao Raisecare Biological Technology Co., Ltd. (“Raisecare”) completed a Series B financing round of over RMB 100 million. The round was led by CITIC Medical Fund, with participation from funds under CICC Capital, Chongqing Yinuo Private Equity Investment Fund Partnership (Limited Partnership), and Qingdao Jufeng Technology Venture Capital Co., Ltd.

Qingdao Raisecare Biological Technology Co., Ltd., established in 2016, is a high-tech enterprise integrating research and development, manufacturing, sales, and services for life science research and in vitro diagnostic (IVD) products. Since its inception, the company has focused on the field of flow cytometry diagnostics, committing to the development of industry-leading detection technologies. It provides innovative comprehensive solutions covering everything from raw materials to product development and clinical application research. Raisecare has now become a leading domestic enterprise in the medical sector related to flow cytometry reagents, with its flow cytometers and series of detection reagents widely used by nearly one thousand hospitals.

In the future, Raisecare will remain true to its original aspiration of striving for the advancement of human health, continuously enhance its innovation capabilities, and forge ahead on a new and higher platform.